-
Ziprasidone HCl: A Mechanistic Assay Framework
2026-09-23
Ziprasidone HCl is more than a receptor pharmacology tool: it offers a testable route for studying GOT1-dependent glutamine metabolism in cancer cells. This article presents an orthogonal assay framework that separates target engagement, metabolic disruption, and phenotype from formulation and receptor-mediated confounders.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-09-23
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide for controlled renin-angiotensin system research involving blood pressure regulation and aldosterone signaling. This guide covers preparation, solvent selection, storage, and assay controls; use should remain within cardiovascular and renal workflows rather than unrelated peptide-signaling studies.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-22
Build reproducible PTEN-restoration assays with Cap 1, pseudouridine-modified, polyadenylated mRNA engineered for efficient mammalian translation. This workflow connects practical handling and delivery optimization with nanoparticle-enabled studies of PI3K/Akt signaling and trastuzumab resistance.
-
Mubritinib (TAK 165) Disrupts KSHV PEL Metabolism
2026-09-21
Calderon and colleagues identified Mubritinib (TAK 165) through complementary screens for inhibitors of KSHV LANA DNA binding and KSHV-positive primary effusion lymphoma growth. The study connects the compound’s selective PEL activity to mitochondrial electron transport chain disruption, altered cellular energy balance, and apoptotic phenotypes rather than conventional HER2 signaling pathway inhibition.
-
Dabigatran Etexilate as an Oral Direct Thrombin Inhibitor
2026-09-21
The 2011 review by Blommel and Blommel positioned dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, connecting prodrug activation and predictable anticoagulation with evidence in venous thromboembolism and nonvalvular atrial fibrillation. Its practical message is qualified: oral dosing and reduced dependence on routine INR monitoring are balanced by renal-function requirements and bleeding or gastrointestinal safety considerations.
-
Catalpol, Glycolysis, and Liver Fibrosis Mechanisms
2026-09-20
The reference study identifies catalpol as an anti-fibrotic agent that suppresses aerobic glycolysis in activated hepatic stellate cells through an EphA2/FAK/Src signaling mechanism. By combining animal models, LX-2 cell experiments, and target-engagement assays, the work connects a metabolic phenotype with a defined receptor-associated signaling pathway and provides a framework for mechanistic liver fibrosis research.
-
Angiotensin (1-7): From RAS Biology to Translation
2026-09-19
Angiotensin (1-7) is more than a counter-regulatory renin–angiotensin system peptide. Its Mas receptor biology, PI3K/AKT and ERK pathway effects, and emerging sequence-dependent behavior create a strategic framework for translational studies spanning fibrosis, inflammation, metabolism, neurobiology, and carefully bounded antiviral research.
-
BFH772 (VEGFR2 inhibitor) Workflow Guide
2026-09-19
BFH772 is a selective small-molecule VEGFR2 inhibitor for biochemical, cellular, and tumor angiogenesis research where controlled pathway modulation and organic-solvent compatibility are required. It should not be used as a water-soluble formulation, a broad-spectrum kinase inhibitor, or a basis for direct clinical conclusions without independent validation.
-
Carbapenemase Transmission in CREC Across Guangdong
2026-09-18
A 2025 BMC Microbiology study characterized carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, revealing frequent blaNDM-1 carriage and highly efficient conjugative transfer. Its combined plasmid-localization, susceptibility, mobile-element, and genotyping workflow provides a practical framework for interpreting multidrug resistance and transmission potential in hospital CREC surveillance.
-
Triptolide A3891: Reliable Cell Assay Design
2026-09-18
This scenario-based guide explains how Triptolide (SKU A3891) can support better-designed viability, proliferation, invasion, and cytotoxicity assays. It connects nanomolar experimental ranges with practical stock preparation, controls, interpretation, and vendor-selection criteria for biomedical researchers.
-
Comparative Gene Expression in the Mammalian Claustrum
2026-09-17
The reference study proposes a cross-mammalian framework for identifying conserved claustrum subdivisions by integrating gene expression, cytoarchitecture, and anatomical position. Its comparative in situ hybridization analysis indicates that molecular and spatial organization is preserved across species with markedly different brain sizes, offering a more stable basis for interpreting claustrum anatomy beyond mouse models.
-
Acifran and HCAR Biology: From Structure to Strategy
2026-09-17
Acifran is more than a receptor agonist for routine lipid assays: recent cryo-EM structures position it as a mechanistic reference for comparing HCAR2/GPR109A and HCAR3/GPR109B. This thought-leadership analysis connects receptor structure, cAMP validation, compound handling, and translational strategy for researchers studying lipid signaling and metabolic disorders.
-
Biotin-HPDP: Reproducible Thiol Labeling
2026-09-16
Learn how Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide), SKU A8008, can complement viability, proliferation, and cytotoxicity assays with reversible thiol-specific protein labeling. This scenario-driven guide covers compatibility, preparation, controls, interpretation, and practical supplier selection.
-
Mubritinib (TAK 165) in Mitochondrial Oncology
2026-09-15
Mubritinib redirects HER2-oriented research toward mitochondrial complex I, oxidative phosphorylation, and ROS-dependent cell death. This workflow shows how to evaluate TAK 165 alone or with cisplatin in NSCLC while extending the strategy to AML and primary effusion lymphoma models.
-
IGFBP2–THBS1 Axis in Growth Hormone Therapy
2026-09-15
The reference study identifies an IGFBP2–THBS1 regulatory axis that connects growth hormone exposure with IGF-1-associated chondrocyte proliferation and hypertrophic differentiation in idiopathic short stature research. Its combination of patient plasma data and gain- and loss-of-function experiments provides a mechanistic framework, while the in vitro design leaves important clinical and in vivo questions unresolved.